Skip to main content
MBX logo

MBX · MBX Biosciences, Inc. · Financials

Track MBX — free
$52.97 +2.68 (+5.33%) At close · Oct 27 Q2 2025 earnings call transcript
Market Cap
$2.42B
Shares
48.16M
Volume · Oct 27 493.02K Avg daily vol (3M) 521.8K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Net Income
-$87M -40.5%
FY2025 Net Income FY2023–FY2025
Diluted EPS
-$2.38 +59.1%
FY2025 Diluted EPS FY2023–FY2025
Operating Cash Flow
-$79.95M -46.2%
FY2025 Operating Cash Flow FY2023–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023
$88.49M $79.16M $57.42M $28.53M
$29.43M $18.9M $10.78M $6.78M
$117.92M $98.06M $68.19M $35.31M
-$117.92M -$98.06M -$68.19M -$35.31M
— -$87M -$61.9M —
— $0 $0 $0
-$104.32M -$87M -$61.92M -$32.56M
-$104.29M -$86.97M -$61.92M -$32.56M
-$105.53M -$86.74M -$61.93M -$32.51M
USD/shares -$2.37 -$2.38 -$5.82 -$31.96
USD/shares -$2.37 -$2.38 -$5.82 -$31.96
shares — 36.51M 10.64M 1.02M
shares — 36.51M 10.64M 1.02M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Debt Profile

Completed filing coverage through Mar 12, 2026

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-06-30 USD 631,000 10-Q filed 2026-08-06
Noncurrent operating lease liabilities 2026-06-30 USD 2,710,000 10-Q filed 2026-08-06
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 9.56×
EV/EBIT
—
Peer median 17.93×
P/E (TTM)
—
Peer median 20.41×

Peer medians compare against the 237 similar-size Biotechnology companies (of 565 listed).

Key facts CIK 1776111 CUSIP 55287L101 13F (30d) 21 filings 21 filers Visit website Investor relations